Paps

ProSomnus Poised to Support Obstructive Sleep Apnea Patients Following Discontinuation of Philips Respironics OSA Devices

Retrieved on: 
Monday, January 29, 2024
Info, Sleep, Patient, PAP, Sleep apnea, Medicare, DDS, Food and Drug Administration, ASBA, Respironics, Obstructive sleep apnea, Food, CPAP, DSM, FDA, Paps, News, Diagnosis, OAT, Physician, Pharmaceutical industry

PLEASANTON, Calif., Jan. 29, 2024 (GLOBE NEWSWIRE) -- ProSomnus, Inc. (NASDAQ: OSA ) (the “Company”), the leading non-CPAP Obstructive Sleep Apnea (OSA) therapy™, announced that the company is well-positioned to support patients with OSA and sleep physicians who can no longer access discontinued OSA devices.

Key Points: 
  • PLEASANTON, Calif., Jan. 29, 2024 (GLOBE NEWSWIRE) -- ProSomnus, Inc. (NASDAQ: OSA ) (the “Company”), the leading non-CPAP Obstructive Sleep Apnea (OSA) therapy™, announced that the company is well-positioned to support patients with OSA and sleep physicians who can no longer access discontinued OSA devices.
  • Earlier in January, Philips Respironics announced the discontinuation of many devices used for the treatment and diagnosis of sleep apnea, including CPAP systems.
  • “Scientific data from over a dozen studies, including hundreds of patients, establish ProSomnus devices as safe, effective, and patient preferred.
  • “Philips has been a prominent player in the sleep health industry, providing innovative solutions for sleep apnea and other sleep disorders.

MERCALIS RELEASES 2023 ANNUAL HIGHLIGHTS

Retrieved on: 
Tuesday, January 9, 2024
Cloud, Royal, PBM, Triangle, Patient, Legislation, Pharmacy, Privacy, Policy, Software as a service, Intelligence, History, Element, PLD, Accreditation, Information, ISMS, Market access, Consumer, Human services, ISO/IEC, Paps, Catalog, Certification, Growth, Management

MORRISVILLE, N.C., Jan. 9, 2024 /PRNewswire/ -- Mercalis Inc., an integrated life sciences commercialization company that provides comprehensive solutions that span the entire biopharmaceutical value chain, today released its 2023 annual highlights, detailing the organization's impressive performance over the past year.

Key Points: 
  • MORRISVILLE, N.C., Jan. 9, 2024 /PRNewswire/ -- Mercalis Inc., an integrated life sciences commercialization company that provides comprehensive solutions that span the entire biopharmaceutical value chain, today released its 2023 annual highlights, detailing the organization's impressive performance over the past year.
  • "Mercalis's success in 2023 was highlighted by a pivotal corporate rebranding," said Scott Dulitz, Mercalis's Chief Executive Officer.
  • Some of Mercalis's more newsworthy items from 2023 include:
    Throughout its history, Mercalis has publicly supported many of the biopharmaceutical industry's efforts to combat legislation and policies that adversely impact patients.
  • After a rigorous recertification process, Mercalis once again achieved the coveted ISO/IEC 27001 accreditation for its Information Security Management System (ISMS).

Big or Small, Red or Blue – States With Laws Protecting Patient Assistance Programs Have Not Seen Health Insurance Premium Hikes

Retrieved on: 
Thursday, July 13, 2023
Alternative Medicine, White House, Federal Government, Healthcare Reform, Health, Public Policy, Foundation, Congressional News, Views, Government, Medical Supplies, Diabetes, Insurance, Human Resources, People with Disabilities, Professional Services, Philanthropy, Health Technology, Parenting, Health Insurance, Advocacy Group Opinion, Women, Telemedicine, Virtual Medicine, Seniors, Other Health, Men, Pharmaceutical, Optical, Family, Oncology, Mental Health, Medical Devices, Consumer, Hospitals, Practice Management, Physical Therapy, Fitness & Nutrition, Managed Care, Dental, General Health, Cardiology, Doctor of Pharmacy, Health insurance marketplace, Robert Wood Johnson Foundation, OOP, ANOVA, Silver, Platinum, Medicine, Pharmacy, MS, Advocacy, Headache, Gold, Affordable Care Act, ACA, Patient, DSM-IV codes, Outreach, PBM, Paps, Chronic condition, Care Act 2014, HIX, Rest, Disease, Conditional sentence, Legislation, Health insurance

In nineteen states, to date, these laws protect patient assistance programs (PAPs) by requiring that the financial assistance given to patients count toward their co-pays, deductibles, and out-of-pocket (OOP) maximums.

Key Points: 
  • In nineteen states, to date, these laws protect patient assistance programs (PAPs) by requiring that the financial assistance given to patients count toward their co-pays, deductibles, and out-of-pocket (OOP) maximums.
  • “Insurance companies assert that restricting accumulator and maximizer programs will cause higher health insurance premiums for everyone, but that claim is false.
  • The second variable analyzed was the introduction of legislation protecting patient assistance programs by prohibiting accumulators and/or maximizers.
  • The analysis shows that across all “metal tiers,” there has been no statistically significant difference in the rates of health insurance premium increases upon passage or implementation of legislation protecting patient assistance programs by prohibiting accumulator and/or maximizer policies.

Triton Benefits & HR Solutions Unveils Game-Changing Approach to Prescription RX Sourcing, Delivering Significant Savings for Clients

Retrieved on: 
Wednesday, June 14, 2023
Payroll, HR, Paps, Adalimumab, RX, Health insurance, Pharmaceutical industry, Ustekinumab, Triton

For example, Triton's global sourcing approach can reduce the cost of a $25,000, 90-milligram prescription of Stelara to just $12,500, delivering substantial savings without compromising on quality or efficacy.

Key Points: 
  • For example, Triton's global sourcing approach can reduce the cost of a $25,000, 90-milligram prescription of Stelara to just $12,500, delivering substantial savings without compromising on quality or efficacy.
  • "We are constantly seeking ways to bring more value to our clients," says Steve Rosenthal, President, and CEO of Triton Benefits & HR Solutions.
  • With this innovative service, Triton continues to revolutionize the industry, setting a new standard for cost-effective, client-centered healthcare benefits and HR solutions.
  • For more information about Triton Benefits & HR Solutions and their innovative healthcare cost reduction strategies, visit their website ( www.TritonHR.com ) or contact them directly at (877) OK-TRITON.

Medvantx Launches Fully Integrated Pharmacy Platform and Appoints Key Executives to Advance Access to Healthcare

Retrieved on: 
Monday, November 7, 2022
Software, Professional Services, Pharmaceutical, Data Management, Technology, Other Manufacturing, Health Technology, Health Insurance, Data Analytics, Transport, Health, Logistics, Supply Chain Management, Manufacturing, People, API, Leadership, VP, Mortality, Therapy, Growth, Compliance, Education, SVP, Multimedia, Business development, Customer experience, Industry, Pembrokeshire Action To Combat Hardship, Pharmacy, Prescription, Safety, Disease, Brigham Young University Museum of Peoples and Cultures, Culture, UPS, CEO, Paps, Topical steroid withdrawal, Foundation, Partnership, Pharmacist, Technology, Patient, Solution, Pharmaceutical industry

Medvantx, a healthcare technology and services company, today launched Medvantx Insights, a fully integrated, non-commercial pharmacy platform, and announced executive leadership expansions to further its mission to advance medication and healthcare access to individuals throughout the country, including those who are underinsured or uninsured.

Key Points: 
  • Medvantx, a healthcare technology and services company, today launched Medvantx Insights, a fully integrated, non-commercial pharmacy platform, and announced executive leadership expansions to further its mission to advance medication and healthcare access to individuals throughout the country, including those who are underinsured or uninsured.
  • The platform delivers operational, compliance and financial insights to manufacturers through advanced analytics and uses API-based integration across technology platforms for seamless access.
  • Medvantx is paving the way for access to critical medication by removing barriers to prescription access for all, said Parthasarathy, CEO of Medvantx.
  • Medvantx is a healthcare technology and services company dedicated to advancing prescription and healthcare access nationwide by connecting patients, providers, and healthcare organizations.

Insights on the Cancer Immunotherapy Global Market to 2027 - by Therapy Type, Application, End-user and Region - ResearchAndMarkets.com

Retrieved on: 
Monday, April 4, 2022
Pharmaceutical, Health, Oncology, Immunotherapy, Growth, Prevalence, Melanoma, Paps, PFS, Immune system, Multiple myeloma, Research, Industry, R, Progression-free survival, Hospital, COVID-19, Cancer, Death, Radiation, Pharmaceutical industry, Potash

It is one of the leading causes of death globally, which is nowadays treated using cancer immunotherapy.

Key Points: 
  • It is one of the leading causes of death globally, which is nowadays treated using cancer immunotherapy.
  • Cancer immunotherapy offers more advantages than conventional anti-tumor therapy that can prolong progression-free survival (PFS) and overall survival (OS).
  • Key Questions Answered in This Report:
    How has the global cancer immunotherapy market performed so far and how will it perform in the coming years?
  • What is the structure of the global cancer immunotherapy market and who are the key players?